Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.14
OMCL's Cash-to-Debt is ranked lower than
91% of the 1913 Companies
in the Global Health Information Services industry.

( Industry Median: 7.63 vs. OMCL: 0.14 )
Ranked among companies with meaningful Cash-to-Debt only.
OMCL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.14  Med: No Debt Max: No Debt
Current: 0.14
Equity-to-Asset 0.49
OMCL's Equity-to-Asset is ranked lower than
66% of the 1790 Companies
in the Global Health Information Services industry.

( Industry Median: 0.60 vs. OMCL: 0.49 )
Ranked among companies with meaningful Equity-to-Asset only.
OMCL' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.57  Med: 0.69 Max: 0.78
Current: 0.49
-0.57
0.78
Piotroski F-Score: 3
Altman Z-Score: 3.38
Beneish M-Score: -2.84
WACC vs ROIC
6.80%
-0.66%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % -2.19
OMCL's Operating Margin % is ranked lower than
70% of the 1871 Companies
in the Global Health Information Services industry.

( Industry Median: 5.10 vs. OMCL: -2.19 )
Ranked among companies with meaningful Operating Margin % only.
OMCL' s Operating Margin % Range Over the Past 10 Years
Min: -2.19  Med: 7.72 Max: 11.25
Current: -2.19
-2.19
11.25
Net Margin % -1.14
OMCL's Net Margin % is ranked lower than
67% of the 1871 Companies
in the Global Health Information Services industry.

( Industry Median: 3.64 vs. OMCL: -1.14 )
Ranked among companies with meaningful Net Margin % only.
OMCL' s Net Margin % Range Over the Past 10 Years
Min: -1.14  Med: 5.1 Max: 20.32
Current: -1.14
-1.14
20.32
ROE % -1.80
OMCL's ROE % is ranked lower than
69% of the 1817 Companies
in the Global Health Information Services industry.

( Industry Median: 6.71 vs. OMCL: -1.80 )
Ranked among companies with meaningful ROE % only.
OMCL' s ROE % Range Over the Past 10 Years
Min: -1.8  Med: 5.35 Max: 25.13
Current: -1.8
-1.8
25.13
ROA % -0.85
OMCL's ROA % is ranked lower than
65% of the 1927 Companies
in the Global Health Information Services industry.

( Industry Median: 3.34 vs. OMCL: -0.85 )
Ranked among companies with meaningful ROA % only.
OMCL' s ROA % Range Over the Past 10 Years
Min: -0.85  Med: 4.01 Max: 17.93
Current: -0.85
-0.85
17.93
ROC (Joel Greenblatt) % -12.23
OMCL's ROC (Joel Greenblatt) % is ranked lower than
69% of the 1889 Companies
in the Global Health Information Services industry.

( Industry Median: 23.72 vs. OMCL: -12.23 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OMCL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -12.23  Med: 45.83 Max: 91.06
Current: -12.23
-12.23
91.06
3-Year Revenue Growth Rate 20.90
OMCL's 3-Year Revenue Growth Rate is ranked higher than
84% of the 1483 Companies
in the Global Health Information Services industry.

( Industry Median: 5.30 vs. OMCL: 20.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OMCL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -53.3  Med: 10.6 Max: 20.9
Current: 20.9
-53.3
20.9
3-Year EBITDA Growth Rate 5.50
OMCL's 3-Year EBITDA Growth Rate is ranked lower than
52% of the 1265 Companies
in the Global Health Information Services industry.

( Industry Median: 6.90 vs. OMCL: 5.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OMCL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -13.6  Med: 18 Max: 121.1
Current: 5.5
-13.6
121.1
3-Year EPS without NRI Growth Rate -69.00
OMCL's 3-Year EPS without NRI Growth Rate is ranked lower than
97% of the 1178 Companies
in the Global Health Information Services industry.

( Industry Median: 7.50 vs. OMCL: -69.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OMCL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -69.7  Med: 7.5 Max: 260.9
Current: -69
-69.7
260.9
GuruFocus has detected 8 Warning Signs with Omnicell Inc $OMCL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OMCL's 30-Y Financials

Financials (Next Earnings Date: 2017-10-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

OMCL Guru Trades in Q3 2016

Ken Fisher 517,464 sh (-3.49%)
» More
Q4 2016

OMCL Guru Trades in Q4 2016

Jim Simons 23,243 sh (New)
Steven Cohen 33,900 sh (New)
Ken Fisher 507,114 sh (-2.00%)
» More
Q1 2017

OMCL Guru Trades in Q1 2017

Mariko Gordon 1,537,954 sh (New)
Jim Simons Sold Out
Steven Cohen Sold Out
Ken Fisher 492,314 sh (-2.92%)
» More
Q2 2017

OMCL Guru Trades in Q2 2017

Joel Greenblatt 33,566 sh (New)
Ken Fisher 492,202 sh (-0.02%)
Mariko Gordon 1,353,369 sh (-12.00%)
» More
» Details

Insider Trades

Latest Guru Trades with OMCL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mariko Gordon 2017-06-30 Reduce -12.00%0.44%$39.55 - $44.4 $ 49.7020%1,353,369
Ken Fisher 2017-06-30 Reduce -0.02%$39.55 - $44.4 $ 49.7020%492,202
Joel Greenblatt 2017-06-30 New Buy0.02%$39.55 - $44.4 $ 49.7020%33,566
Mariko Gordon 2017-03-31 New Buy3.64%$32.15 - $40.65 $ 49.7035%1,537,954
Ken Fisher 2017-03-31 Reduce -2.92%$32.15 - $40.65 $ 49.7035%492,314
Ken Fisher 2016-12-31 Reduce -2.00%$31.2 - $37.95 $ 49.7044%507,114
Ken Fisher 2016-09-30 Reduce -3.49%$35.11 - $40.4 $ 49.7033%517,464
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Application Software » Health Information Services    NAICS: 621999    SIC: 8099
Compare:NAS:INOV, NAS:PINC, NYSE:TDOC, NYSE:EVH, NAS:WBMD, NAS:HQY, NAS:QSII, NAS:HSTM, NAS:NH, NAS:CPSI, NAS:RCM, NAS:TRHC, OTCPK:MDXL, XCNQ:AHG, OTCPK:CNAB, OTCPK:HCRE, OTCPK:CRGS, OTCPK:OMCM, OTCPK:HLYK, NAS:STRM » details
Traded in other countries:OC9.Germany,
Headquarter Location:USA
Omnicell Inc provides automation and business analytics software solutions for patient-centric medication and supplies management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing.

Omnicell provides automation and business analytics software for healthcare providers. The firm operates in two segments: automation and analytics and medication adherence. The automation and analytics segment manufactures medication dispensing systems, pharmacy inventory management systems, and related software. This segment contributes the majority of revenue. The medication adherence segment sells products like consumable medication blister cards and packaging equipment to help administer medication outside of a hospital setting. Omnicell generates the vast majority of its revenue in the United States.

Top Ranked Articles about Omnicell Inc

Omnicell Announces Enhancements to its Patient Management Access Portal (PMAP) for Improved Patient Adherence and Pharmacy Workflow
Greater Hudson Valley Health System Adds New XT Series to Expand Omnicell Partnership
White River Health System Selects Omnicell's Medication Management Solutions for Patient Safety and Long-Term Success
Omnicell Launches XT Series Automated Dispensing Cabinets for Supply Management
Omnicell to Release Second Quarter 2017 Earnings Results on July 27, 2017
CompleteRx Partners with Omnicell to Support the Commonwealth of Massachusetts State Office of Pharmacy Services
MACH4 Pharma Systems Receives German Global Health Award for South Africa Pharmacy Access Initiative
Mariko Gordon Invests in 6 Technology Companies 2 positions are now among guru’s top 10 holdings
Daruma Capital Management founder Mariko Gordon (Trades, Portfolio) gained 20 new positions in the first quarter. Among her purchases were six technology stocks – Omnicell Inc. (NASDAQ:OMCL), Veeco Instruments Inc. (NASDAQ:VECO), Xperi Corp. (NASDAQ:XPER), II-VI Inc. (NASDAQ:IIVI), Pros Holdings Inc. (NYSE:PRO) and Bazaarvoice Inc. (NASDAQ:BV). Read more...
Omnicell Adds to Product Offerings in Canada Through Agreement with McKesson Canada
Southcoast Health Selects Omnicell's Medication Management and Analytics Solutions for Installation Across Multiple Facilities

Ratios

vs
industry
vs
history
Forward PE Ratio 38.46
OMCL's Forward PE Ratio is ranked lower than
72% of the 278 Companies
in the Global Health Information Services industry.

( Industry Median: 23.70 vs. OMCL: 38.46 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 53.85
OMCL's Price-to-Owner-Earnings is ranked lower than
85% of the 727 Companies
in the Global Health Information Services industry.

( Industry Median: 25.49 vs. OMCL: 53.85 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
OMCL' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.72  Med: 35.78 Max: 3988.33
Current: 53.85
7.72
3988.33
PB Ratio 4.11
OMCL's PB Ratio is ranked lower than
56% of the 1749 Companies
in the Global Health Information Services industry.

( Industry Median: 3.07 vs. OMCL: 4.11 )
Ranked among companies with meaningful PB Ratio only.
OMCL' s PB Ratio Range Over the Past 10 Years
Min: 0.96  Med: 2.36 Max: 6.93
Current: 4.11
0.96
6.93
PS Ratio 2.71
OMCL's PS Ratio is ranked higher than
51% of the 1786 Companies
in the Global Health Information Services industry.

( Industry Median: 2.47 vs. OMCL: 2.71 )
Ranked among companies with meaningful PS Ratio only.
OMCL' s PS Ratio Range Over the Past 10 Years
Min: 0.94  Med: 2.16 Max: 4.69
Current: 2.71
0.94
4.69
Price-to-Free-Cash-Flow 33.13
OMCL's Price-to-Free-Cash-Flow is ranked lower than
66% of the 662 Companies
in the Global Health Information Services industry.

( Industry Median: 25.12 vs. OMCL: 33.13 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
OMCL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.02  Med: 30.62 Max: 295
Current: 33.13
8.02
295
Price-to-Operating-Cash-Flow 26.43
OMCL's Price-to-Operating-Cash-Flow is ranked lower than
72% of the 829 Companies
in the Global Health Information Services industry.

( Industry Median: 18.90 vs. OMCL: 26.43 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
OMCL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.98  Med: 20.77 Max: 10100
Current: 26.43
6.98
10100
EV-to-EBIT -136.12
OMCL's EV-to-EBIT is ranked lower than
99.99% of the 1265 Companies
in the Global Health Information Services industry.

( Industry Median: 18.76 vs. OMCL: -136.12 )
Ranked among companies with meaningful EV-to-EBIT only.
OMCL' s EV-to-EBIT Range Over the Past 10 Years
Min: -142.8  Med: 23.5 Max: 253.4
Current: -136.12
-142.8
253.4
EV-to-EBITDA 50.41
OMCL's EV-to-EBITDA is ranked lower than
81% of the 1363 Companies
in the Global Health Information Services industry.

( Industry Median: 14.91 vs. OMCL: 50.41 )
Ranked among companies with meaningful EV-to-EBITDA only.
OMCL' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.7  Med: 15.5 Max: 52.9
Current: 50.41
3.7
52.9
Shiller PE Ratio 115.18
OMCL's Shiller PE Ratio is ranked lower than
81% of the 320 Companies
in the Global Health Information Services industry.

( Industry Median: 38.11 vs. OMCL: 115.18 )
Ranked among companies with meaningful Shiller PE Ratio only.
OMCL' s Shiller PE Ratio Range Over the Past 10 Years
Min: 36.8  Med: 56.23 Max: 119.83
Current: 115.18
36.8
119.83
Current Ratio 1.40
OMCL's Current Ratio is ranked lower than
65% of the 1873 Companies
in the Global Health Information Services industry.

( Industry Median: 1.97 vs. OMCL: 1.40 )
Ranked among companies with meaningful Current Ratio only.
OMCL' s Current Ratio Range Over the Past 10 Years
Min: 0.64  Med: 2.4 Max: 5.21
Current: 1.4
0.64
5.21
Quick Ratio 1.01
OMCL's Quick Ratio is ranked lower than
76% of the 1873 Companies
in the Global Health Information Services industry.

( Industry Median: 1.85 vs. OMCL: 1.01 )
Ranked among companies with meaningful Quick Ratio only.
OMCL' s Quick Ratio Range Over the Past 10 Years
Min: 0.4  Med: 2.02 Max: 4.95
Current: 1.01
0.4
4.95
Days Inventory 71.61
OMCL's Days Inventory is ranked lower than
80% of the 1089 Companies
in the Global Health Information Services industry.

( Industry Median: 16.93 vs. OMCL: 71.61 )
Ranked among companies with meaningful Days Inventory only.
OMCL' s Days Inventory Range Over the Past 10 Years
Min: 35.43  Med: 54.71 Max: 71.61
Current: 71.61
35.43
71.61
Days Sales Outstanding 81.04
OMCL's Days Sales Outstanding is ranked lower than
55% of the 1484 Companies
in the Global Health Information Services industry.

( Industry Median: 66.73 vs. OMCL: 81.04 )
Ranked among companies with meaningful Days Sales Outstanding only.
OMCL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.2  Med: 69.17 Max: 84.02
Current: 81.04
56.2
84.02
Days Payable 50.90
OMCL's Days Payable is ranked lower than
58% of the 1335 Companies
in the Global Health Information Services industry.

( Industry Median: 44.68 vs. OMCL: 50.90 )
Ranked among companies with meaningful Days Payable only.
OMCL' s Days Payable Range Over the Past 10 Years
Min: 26.08  Med: 34.86 Max: 50.9
Current: 50.9
26.08
50.9

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.50
OMCL's 3-Year Average Share Buyback Ratio is ranked higher than
58% of the 1200 Companies
in the Global Health Information Services industry.

( Industry Median: -2.40 vs. OMCL: -1.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OMCL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -140.8  Med: -3.3 Max: 1.6
Current: -1.5
-140.8
1.6

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.13
OMCL's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
56% of the 862 Companies
in the Global Health Information Services industry.

( Industry Median: 2.01 vs. OMCL: 2.13 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
OMCL' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.94  Med: 1.52 Max: 8.67
Current: 2.13
0.94
8.67
Price-to-Median-PS-Value 1.26
OMCL's Price-to-Median-PS-Value is ranked higher than
53% of the 1679 Companies
in the Global Health Information Services industry.

( Industry Median: 1.14 vs. OMCL: 1.26 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OMCL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.25  Med: 1.03 Max: 2.27
Current: 1.26
0.25
2.27
Earnings Yield (Greenblatt) % -0.74
OMCL's Earnings Yield (Greenblatt) % is ranked lower than
68% of the 1927 Companies
in the Global Health Information Services industry.

( Industry Median: 2.41 vs. OMCL: -0.74 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OMCL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -0.8  Med: 4 Max: 19
Current: -0.74
-0.8
19
Forward Rate of Return (Yacktman) % 10.81
OMCL's Forward Rate of Return (Yacktman) % is ranked higher than
68% of the 792 Companies
in the Global Health Information Services industry.

( Industry Median: 10.91 vs. OMCL: 10.81 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
OMCL' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -2.5  Med: 26.3 Max: 43.9
Current: 10.81
-2.5
43.9

More Statistics

Revenue (TTM) (Mil) $680.15
EPS (TTM) $ -0.21
Beta0.83
Short Percentage of Float12.04%
52-Week Range $30.35 - 51.98
Shares Outstanding (Mil)37.45

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 734 822
EPS ($) 1.28 2.11
EPS without NRI ($) 1.28 2.11
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for OMCL

Headlines

Articles On GuruFocus.com
Omnicell Announces Enhancements to its Patient Management Access Portal (PMAP) for Improved Patient Aug 16 2017 
Greater Hudson Valley Health System Adds New XT Series to Expand Omnicell Partnership Jul 26 2017 
White River Health System Selects Omnicell's Medication Management Solutions for Patient Safety and Jul 25 2017 
Omnicell Launches XT Series Automated Dispensing Cabinets for Supply Management Jul 24 2017 
Omnicell to Release Second Quarter 2017 Earnings Results on July 27, 2017 Jul 21 2017 
CompleteRx Partners with Omnicell to Support the Commonwealth of Massachusetts State Office of Pharm Jun 12 2017 
MACH4 Pharma Systems Receives German Global Health Award for South Africa Pharmacy Access Initiative Jun 08 2017 
Mariko Gordon Invests in 6 Technology Companies May 22 2017 
Omnicell Adds to Product Offerings in Canada Through Agreement with McKesson Canada May 09 2017 
Southcoast Health Selects Omnicell's Medication Management and Analytics Solutions for Installation May 02 2017 

More From Other Websites
Omnicell Upgrades Web Portal, Grows in Medication Management Aug 17 2017
Omnicell Announces Enhancements to its Patient Management Access Portal (PMAP) for Improved Patient... Aug 16 2017
Edited Transcript of OMCL earnings conference call or presentation 27-Jul-17 8:30pm GMT Aug 12 2017
Omnicell (OMCL) Earnings Meet, Revenues Beat Estimates in Q2 Jul 31 2017
Omnicell (OMCL) Catches Eye: Stock Moves 13.5% Higher Jul 31 2017
Omnicell tops Street 2Q forecasts Jul 28 2017
Omnicell Achieves Record Revenue in the Second Quarter 2017 Jul 27 2017
Greater Hudson Valley Health System Adds New XT Series to Expand Omnicell Partnership Jul 26 2017
White River Health System Selects Omnicell's Medication Management Solutions for Patient Safety and... Jul 25 2017
Omnicell Launches XT Series Automated Dispensing Cabinets for Supply Management Jul 24 2017
Omnicell to Release Second Quarter 2017 Earnings Results on July 27, 2017 Jul 21 2017
ETFs with exposure to Omnicell, Inc. : July 10, 2017 Jul 10 2017
Omnicell (OMCL) Rides on Acquisitions Amid Tough Competition Jul 05 2017
ETFs with exposure to Omnicell, Inc. : June 27, 2017 Jun 27 2017
Omnicell, Inc. :OMCL-US: Earnings Analysis: Q1, 2017 By the Numbers : June 26, 2017 Jun 26 2017
CompleteRx Partners with Omnicell to Support the Commonwealth of Massachusetts State Office of... Jun 12 2017
Why Is Omnicell (OMCL) Up 3.3% Since the Last Earnings Report? Jun 09 2017
MACH4 Pharma Systems Receives German Global Health Award for South Africa Pharmacy Access Initiative Jun 08 2017
Omnicell, Inc. breached its 50 day moving average in a Bullish Manner : OMCL-US : June 2, 2017 Jun 02 2017
Omnicell Showcases Portfolio of Award-Winning Medication Management Solutions at Annual ASHP Summer... Jun 01 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}